Entero Therapeutics regains Nasdaq compliance after annual meeting

Published 08/07/2025, 21:48
Entero Therapeutics regains Nasdaq compliance after annual meeting

Entero Therapeutics, Inc. (NASDAQ:ENTO), currently trading at $0.53 with a market capitalization of $2.57 million, announced Tuesday that it has regained compliance with Nasdaq Listing Rule 5620(a) following the successful holding of its annual meeting on June 30. According to a letter received from the Listing Qualifications department of The Nasdaq Stock Market LLC, the company’s compliance status has been restored and the matter is now closed.

The notification to Entero Therapeutics was disclosed in a press release statement and referenced a previous Current Report on Form 8-K filed with the Securities and Exchange Commission on July 2. The company’s shares continue to be listed on the Nasdaq Capital Market.

The information in this article is based on a statement from an SEC filing.

In other recent news, Entero Therapeutics, Inc. announced it has received an extension from the Nasdaq Stock Market to regain compliance with the minimum stockholders’ equity requirement for its continued listing on the Nasdaq Capital Market. This extension allows the company until October 8, 2025, to meet the necessary requirements outlined in Nasdaq Listing Rule 5550(b)(1). The company had previously been notified of non-compliance due to a reported negative stockholders’ equity of $3.87 million as of December 31, 2024, which falls short of the required minimum of $2.5 million. Entero Therapeutics has expressed its intention to submit a compliance plan within the specified timeframe. If the plan is accepted, the company may receive additional time to meet the requirements. However, there is no assurance that the plan will be accepted or that the company will successfully regain compliance. Failure to comply could lead to delisting, although Entero has the option to appeal any delisting determination to a Nasdaq Hearing Panel.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.